Company news
Quantum Cyber N.V. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Mainz Biomed to Host Key Opinion Leader Event at DDW 2022
May 8, 2022
Mainz Biomed Provides Product Development Update on PancAlert
May 4, 2022
Mainz Biomed Appoints Darin Leigh as Chief Commercial Officer
April 25, 2022
Mainz Biomed Announces First Quarter 2022 Results
April 11, 2022
Mainz Biomed Completes Successful Pre-Submission Process with the U.S FDA for ColoAlert’s Pivotal Clinical Trial
March 30, 2022
Mainz Biomed to Ring Nasdaq Stock Market Closing Bell
March 20, 2022
Mainz Biomed Appoints Key Clinical Trial Partners for ColoFuture Study
March 16, 2022
Mainz Biomed Announces Year End 2021 Results
March 8, 2022
Mainz Biomed and Partners Join International Awareness Campaign for Colorectal Cancer Awareness Month
March 1, 2022
Mainz Biomed Provides U.S. Regulatory Review Update for ColoAlert
February 22, 2022
Mainz Biomed Expands ColoAlert Commercialization with German Laboratory MVZ Dr. Stein + Kollegen, Mönchengladbach
February 13, 2022
Mainz Biomed Appoints Oncology Expert Dr. Rainer Metzger to Strategic Advisory Board
February 8, 2022
Mainz Biomed Initiates Clinical Study to Evaluate Integrating Novel mRNA Biomarkers Into ColoAlert
February 3, 2022
Mainz Biomed Announces the Closing of its $25.8 Million Public Follow-on Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
January 27, 2022
Mainz Biomed Appoints Steve Quinn as VP Business Development
January 26, 2022
Mainz Biomed Announces Pricing of Follow-on Offering
January 25, 2022
Mainz Biomed Engages DCN Dx to Support Clinical Study Evaluating Novel mRNA Biomarkers for Potential Integration into ColoAlert
January 18, 2022
Mainz Biomed Appoints Michele Pedrocchi, Former Head of Roche Diagnostics Business Development, to Strategic Advisory Board
January 11, 2022
Mainz Biomed Acquires Exclusive Rights to Novel mRNA Biomarkers
January 4, 2022
Mainz BioMed Appoints Karen Richards as Vice President, Regulatory Affairs to Lead US FDA Approval Process
December 20, 2021
Mainz Biomed Expands ColoAlert Commercialization with GANZIMMUN Diagnostics in Europe
December 13, 2021
Mainz Biomed Launches Ecommerce Store for ColoAlert to Assist Patient Access during Covid-19 Pandemic
December 6, 2021
Mainz Biomed Establishes Partnership with Precision for Medicine to Support ColoAlert’s U.S. Regulatory and Commercial Strategy
November 29, 2021
Mainz Biomed Appoints Dr. Soren Thestrup-Nielsen M.D. to Strategic Advisory Board
November 17, 2021
Mainz Biomed to Exhibit ColoAlert at MEDICA 2021, the World’s Largest Medical Trade Fair
November 14, 2021
Mainz Biomed Appoints Former Roche Division President Heiner Dreismann to Strategic Advisory Board
November 10, 2021
Mainz Biomed Commences Trading on Nasdaq Under Ticker Symbol ‘MYNZ’
November 7, 2021
Mainz Biomed Announces Exercise of Over-Allotment Option
November 7, 2021
MYNZ Closes Its First Day of Trading on the Nasdaq Capital Market
November 4, 2021
Decks
- Investor Presentation (September 2026)
Investor deck · 14 slides · Sep 25, 2026
- Investor Presentation (July 2026)
Investor deck · 21 slides · Jul 24, 2026
- Investor Presentation (June 2026)
Investor deck · 19 slides · Jun 3, 2026